We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial.
- Authors
Boccardo, F; Rubagotti, A; Guglielmini, P; Fini, A; Paladini, G; Mesiti, M; Rinaldini, M; Scali, S; Porpiglia, M; Benedetto, C; Restuccia, N; Buzzi, F; Franchi, R; Massidda, B; Distante, V; Amadori, D; Sismondi, P
- Abstract
Tamoxifen, for many years the 'gold standard' in the adjuvant setting for the management of endocrine sensitive early breast cancer, is associated with an increased risk of endometrial cancer and other life-threatening events. Moreover, many women relapse during or after tamoxifen therapy due to the development of resistance. This provided the rationale for a switching trial with anastrozole, the updated results of which are reported here.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Vol 17 Suppl 7, pvii10
- ISSN
1569-8041
- Publication type
Journal Article
- DOI
10.1093/annonc/mdl941